Preliminary trial results demonstrated that Imfinzi plus chemo improved event-free survival in resectable early-stage gastric ...

Tislelizumab plus chemotherapy received FDA approval as a frontline therapy for individuals with unresectable or metastatic ...

Among patients with early-stage triple-negative breast cancer, a beneficial pathologic complete response rate was higher in ...

AstraZeneca's Imfinzi perioperative regimen improved event-free survival in gastric and GEJ cancer. The trial showed a strong ...

British royal family news divulges that Prince William and Princess Catherine, the Duke and Duchess of Wales are in a new era ...

MATTERHORN is the first global phase 3 trial to show improved event-free survival with an immunotherapy combo vs standard ...

The NHS should follow Denmark and offer chemotherapy at home, a leading MP has said. Sir Geoffrey Clifton-Brown, the Tory MP who chairs the public accounts committee, urged the health service to learn ...

A recent study shows that breast cancer survivors who undergo chemotherapy face prolonged physical decline, including fatigue ...

Breast cancer survivors treated with chemotherapy tend to suffer a longer-lasting decline in their physical health, compared ...

Tislelizumab plus chemotherapy is now FDA-approved for metastatic esophageal squamous cell carcinoma with a tumor PD-L1 ...

The Food and Drug Administration (FDA) has approved Tevimbra® (tislelizumab-jsgr), in combination with platinum-containing chemotherapy, for the ...

Researchers from the University of Chicago Medicine Comprehensive Cancer Center have demonstrated the potential of a novel ...